Trump Orders MMR Vaccine Split Into Three Shots. Manufacturers Say That Could Take Years and Millions of Dollars.

President Trump signed an executive order Monday, August 10, in the Oval Office, directing federal health agencies to develop plans within 90 days for splitting the combined measles-mumps-rubella (MMR) vaccine into three individual shots and spacing out other childhood immunizations, according to the Associated Press. Health and Human Services Secretary Robert F. Kennedy Jr. was present for the signing.

Every MMR vaccine approved by the FDA right now is a combination shot. There is no standalone measles vaccine, mumps vaccine, or rubella vaccine currently sold in the United States, according to the AP. That three-in-one approach has been standard since the early 1970s.

So this order doesn't just change a recommendation. It asks drugmakers to build products that don't exist anymore, get them through FDA review, and scale up manufacturing to cover millions of doses a year.

What the order actually does

The directive tells federal officials to draft implementation plans for unbundling MMR and spacing out other shots on the childhood schedule, according to the AP and KOB4. Ground News reported the order covers a schedule of 11 vaccinations total.

Critically, the order doesn't and can't force anyone to comply. States, not the federal government, set school vaccination requirements. Ground News reported the White House is recommending states update their own laws, but compliance would be voluntary, not federally mandated. That's a meaningful check on how much practical impact this order has in the near term.

The manufacturing math

Dr. Jesse Goodman, a former FDA vaccine chief now at Georgetown University, told the AP that companies would likely need to run large new clinical studies to prove standalone shots produce the same immune response as the current combination version. How much old data can be reused is an open question. "The question is how much has changed since then and how comfortable will the FDA and the companies be relying on those comparisons?" Goodman said.

The Los Angeles Times reported that individual measles shots haven't been widely produced in the U.S. for roughly half a century. New manufacturing facilities would need their own safety sign-off, separate from the product studies themselves.

Pharmaceutical scientists and former regulators told the AP this whole process would likely take years, not months, and cost drugmakers tens of millions of dollars in studies and plant construction. The 90-day planning window in the order is just for federal agencies to sketch a path forward, not for shots to actually hit pharmacy shelves.

The parent and provider cost

Right now, a child gets the MMR vaccine in two doses, typically at 12-15 months and again between ages 4 and 6, per CDC guidance cited by KVIA. Splitting that into three separate injections and spreading it across more visits, as Ground News reported, could mean six office visits instead of two just for MMR. Add in spacing out other vaccines and pediatric visits multiply fast.

More visits means more co-pays, more time off work for parents, more strain on pediatric offices already stretched thin, and higher costs tied to syringes and supplies, according to the AP's reporting picked up across PBS, KSL, AOL and U.S. News.

Where the science stands

Dr. Anna Durbin of the Johns Hopkins Bloomberg School of Public Health said: "We do things that are less convenient and more expensive if there's a good reason to do it. There is no good justification for this. I think it's very bad public health policy," she told the AP.

Studies in the U.S. and other countries have shown combination vaccines increase the odds kids are fully vaccinated before starting school, according to the AP. That's the core public health argument against this order: more appointments generally means more missed appointments and more partially vaccinated kids, not fewer side effects.

Supporters of spacing out shots argue parents should have more choice in how and when their kids are vaccinated, and that a federal push toward flexibility, even symbolic, signals the administration takes parental concerns about vaccine schedules seriously. That's a legitimate policy preference. It's a separate question from whether the current combination approach lacks scientific justification, which is what Durbin and the AP's sourcing dispute.

Ground News flagged that this vaccine push is landing three months ahead of the midterm elections.

No manufacturer has announced plans to build standalone MMR production lines. No FDA approval timeline exists yet. The 90-day clock for federal agencies to produce a plan runs out in early November.